Personalis expands tempus strategic collaboration to bring ultra-sensitive cancer recurrence testing to colorectal cancer patients

Fremont, calif.--(business wire)--personalis, inc. (nasdaq: psnl) today announced an expansion and extension of its strategic collaboration with tempus ai, inc. (nasdaq: tem), adding a new indication, colorectal cancer (crc), to the existing, exclusive commercialization agreement. the update means personalis and tempus will now work to bring to market the next personal® ultra-sensitive, tumor-informed minimal residual disease (mrd) test to detect cancer recurrence in four areas: breast, lung an.
TEM Ratings Summary
TEM Quant Ranking